Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?

With an increased understanding of the tumor biology of squamous cell carcinoma of the head and neck (SCCHN), targeted therapies have found their way into the clinical treatment routines against this entity. Nevertheless, to date platinum-based cytostatic agents remain the first line choice and targ...

Descripción completa

Detalles Bibliográficos
Autores principales: von der Grün, Jens, Rödel, Franz, Brandts, Christian, Fokas, Emmanouil, Guckenberger, Matthias, Rödel, Claus, Balermpas, Panagiotis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521064/
https://www.ncbi.nlm.nih.gov/pubmed/30987257
http://dx.doi.org/10.3390/cancers11040472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521064/
https://www.ncbi.nlm.nih.gov/pubmed/30987257
http://dx.doi.org/10.3390/cancers11040472

Ejemplares similares